SEC Form 4 · accession 0001209191-17-018033
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gil M Labrucherie
Officer — SVP & Chief Financial Officer
Period of report
Mar 2, 2017
Accepted (ET)
Mar 3, 2017 · 7:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 2, 2017 | M | 167,506 | $6.34 | A | 236,776 | D | |
| Common StockF1,F3,F2 | Mar 2, 2017 | S | 167,506 | $15.15 | D | 69,270 | D | |
| Common StockF1,F2 | Mar 3, 2017 | M | 7,494 | $6.34 | A | 76,764 | D | |
| Common StockF1,F4,F2 | Mar 3, 2017 | S | 7,494 | $15.21 | D | 69,270 | D | |
| Common StockF5,F2 | Mar 3, 2017 | M | 25,000 | $9.24 | A | 94,270 | D | |
| Common StockF5,F4,F2 | Mar 3, 2017 | S | 25,000 | $15.21 | D | 69,270 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $6.34 | Mar 2, 2017 | M | 167,506 | D | Jun 10, 2013 | Jun 9, 2017 | Common Stock | 167,506 | 7,494 | D |
| Stock OptionF1 | $6.34 | Mar 3, 2017 | M | 7,494 | D | Jun 10, 2013 | Jun 9, 2017 | Common Stock | 7,494 | 0 | D |
| Stock OptionF5 | $9.24 | Mar 3, 2017 | M | 25,000 | D | Nov 18, 2013 | Nov 17, 2017 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017.
- F2This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
- F3This transaction was executed in multiple trades at prices ranging from $15.00 to $15.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- F4This transaction was executed in multiple trades at prices ranging from $15.00 to $15.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- F5This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 25,000 stock options scheduled to expire on November 17, 2017.